Market Overview:
The global daptomycin market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of infectious diseases, increasing demand for novel antibiotics, and growing awareness about antibiotic resistance. Based on type, the global daptomycin market is segmented into 350 mg lyophilized powder and 500 mg lyophilized powder. The 350 mg lyophilized powder segment is expected to account for a larger share of the market in 2018 owing to its lower price point as compared to 500 mg lyophilized powder. However, the 500 mg lyophilized powder segment is projected to grow at a higher CAGR during the forecast period due to its higher efficacy and better patient compliance rates. Based on application, the global daptomycin market is divided into adult patients and pediatric patients (1-17 years of age). The adult patients segment accounted for a larger share of the market in 2017 owingtoits high prevalence rateofinfectious diseases worldwide.
Product Definition:
Daptomycin is a lipopeptide antibiotic used to treat infections caused by Gram-positive bacteria, including MRSA. It is administered intravenously.
350 mg Lyophilized Powder:
350 mg Lyophilized Powder is a form of Daptomycin used for the treatment of bacterial infections in patients with weak immune systems. The drug has gained popularity among healthcare professionals as well as consumers owing to its ability to fight against bacteria and viruses, including the common cold. 350 mg lyophilized powder is also used for treating urinary tract infections (UTIs) caused by E. coli and Proteus species, which are commonly found in women during pregnancy and childbirth.
500 mg Lyophilized Powder:
500 mg Lyophilized Powder is used in the treatment of skin infections and bacterial meningitis. It contains Daptomycin which is a semi-synthetic antibiotic belonging to the class of polymyxins. 500 mg lyophilized powder is produced by fermentation of bacteria (Bacillus) which has been genetically modified to produce large quantities of Daptomycin, thus increasing its efficacy and stability.
Application Insights:
The global daptomycin market by application is categorized into adult and pediatric patients. The use of daptomycin in the treatment of skin infections is expected to drive the demand for the drug in this segment. In addition, increasing awareness regarding diseases such as periodontitis, Crohn¢â‚¬â„¢s disease, and ulcerative colitis among adults is expected to propel growth during the forecast period.
Daptomycin has been used successfully for treating several types of bacterial infections including acute respiratory tract infection (ARTI), skin & soft tissue infection (SSTI), bone & joint infection (BJIs) due to its strong anti-bacterial property against various microorganisms including methicillin-resistant Staphylococcus aureus (MRSA). This factor coupled with rising prevalence rates of BJIs across developed countries such as Germany and France will boost demand over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to increasing cases of infections caused by resistant bacteria, rising healthcare expenditure and favorable reimbursement policies for antibiotic use in this region. Asia Pacific is anticipated to witness lucrative growth over the coming years owing to increasing awareness regarding daptomycin among physicians and patients as well as growing demand for generic drugs from countries such as India, China and Japan.
Moreover, an increase in healthcare expenditure coupled with rising patient awareness regarding treatment options other than antibiotics will drive regional growth over the forecast period. In addition, a rise in number of product approvals from 2018 till date will also contribute towards market development within this region (Japan). For instance; In March 2016; Eisai Co., Ltd.
Growth Factors:
- Increasing incidence of bacterial infections: The increasing incidence of bacterial infections is one of the key growth drivers for the Daptomycin market. This is because Daptomycin is an effective antibiotic against a wide range of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
- Rising demand for novel antibiotics: The rising demand for novel antibiotics to treat resistant strains of bacteria is another key growth driver for the Daptomycin market. This is because Daptomycin has been shown to be highly effective against MRSA and other multi-drug resistant strains of bacteria.
- Growing awareness about the benefits of Daptomycin: There has been a growing awareness about the benefits of using Daptomycin in recent years, which has helped to drive its uptake in both developed and developing countries alike.
- Availability and affordability: One major factor that has helped to drive uptake of this drug globally is its availability and affordability relative to other antibiotics on the market today. This makes it accessible to a wider population base across different geographies .
Scope Of The Report
Report Attributes
Report Details
Report Title
Daptomycin Market Research Report
By Type
350 mg Lyophilized Powder, 500 mg Lyophilized Powder
By Application
Adult, Pediatric Patients (1 to 17 years of age)
By Companies
Merck & Co., Pfizer, Teva, Mylan, Fresenius Kabi, Sagent Pharmaceuticals, Xellia, Hisun, HENGRUI PHARMA, Huadong Medicine, Merck & Co.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
161
Number of Tables & Figures
113
Customization Available
Yes, the report can be customized as per your need.
Global Daptomycin Market Report Segments:
The global Daptomycin market is segmented on the basis of:
Types
350 mg Lyophilized Powder, 500 mg Lyophilized Powder
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adult, Pediatric Patients (1 to 17 years of age)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co.
- Pfizer
- Teva
- Mylan
- Fresenius Kabi
- Sagent Pharmaceuticals
- Xellia
- Hisun
- HENGRUI PHARMA
- Huadong Medicine
- Merck & Co.
Highlights of The Daptomycin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 350 mg Lyophilized Powder
- 500 mg Lyophilized Powder
- By Application:
- Adult
- Pediatric Patients (1 to 17 years of age)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Daptomycin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Daptomycin is a type of antibiotic that is used to treat a variety of infections, including tuberculosis (TB). Daptomycin works by killing the bacteria responsible for TB.
Some of the major companies in the daptomycin market are Merck & Co., Pfizer, Teva, Mylan, Fresenius Kabi, Sagent Pharmaceuticals, Xellia, Hisun, HENGRUI PHARMA, Huadong Medicine, Merck & Co..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Daptomycin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Daptomycin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Daptomycin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Daptomycin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Daptomycin Market Size & Forecast, 2020-2028
4.5.1 Daptomycin Market Size and Y-o-Y Growth
4.5.2 Daptomycin Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 350 mg Lyophilized Powder
5.2.2 500 mg Lyophilized Powder
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Adult
6.2.2 Pediatric Patients (1 to 17 years of age)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Daptomycin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Daptomycin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 350 mg Lyophilized Powder
9.6.2 500 mg Lyophilized Powder
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Adult
9.10.2 Pediatric Patients (1 to 17 years of age)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 350 mg Lyophilized Powder
10.6.2 500 mg Lyophilized Powder
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Adult
10.10.2 Pediatric Patients (1 to 17 years of age)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 350 mg Lyophilized Powder
11.6.2 500 mg Lyophilized Powder
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Adult
11.10.2 Pediatric Patients (1 to 17 years of age)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 350 mg Lyophilized Powder
12.6.2 500 mg Lyophilized Powder
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Adult
12.10.2 Pediatric Patients (1 to 17 years of age)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 350 mg Lyophilized Powder
13.6.2 500 mg Lyophilized Powder
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Adult
13.10.2 Pediatric Patients (1 to 17 years of age)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Daptomycin Market: Competitive Dashboard
14.2 Global Daptomycin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck & Co.
14.3.2 Pfizer
14.3.3 Teva
14.3.4 Mylan
14.3.5 Fresenius Kabi
14.3.6 Sagent Pharmaceuticals
14.3.7 Xellia
14.3.8 Hisun
14.3.9 HENGRUI PHARMA
14.3.10 Huadong Medicine
14.3.11 Merck & Co.
